Should you mix and match your COVID-19 booster vaccines?

Embargoed until: Publicly released: 2022-08-11 01:00

International

A small study has shown that using the Johnson & Johnson vaccine as a booster in people who had a primary course of the Pfizer vaccine resulted in longer-lasting antibody responses than when using the Pfizer vaccine again as a booster. The Johnson & Johnson booster also seemed to generate a better Omicron-specific T-cell response. The authors say this suggests that there may be some immune benefits of mixing-and-matching COVID-19 vaccines.

Media release

From:

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Journal/
conference: JAMA Network Open

Research:Paper

Organisation/s: Beth Israel Deaconess Medical Center, USA

Funder: The authors acknowledge Janssen Vaccines & Prevention, National Institutes of Health (NIH) grant CA260476, the Massachusetts Consortium for Pathogen Readiness, the Ragon Institute, and the Musk Foundation (Dr Barouch). The authors also acknowledge NIH grant CA260543 (Dr Baric) and the Reproductive Scientist Development Program from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and BurroughsWellcome Fund HD000849 (Dr Collier).

Media Contact/s

Contact details are only visible to registered journalists.